Zhou, Keshu
Wang, Tingyu
Pan, Ling
Xu, Wei
Jin, Jie
Zhang, Wei
Hu, Yu
Hu, Jianda
Feng, Ru
Li, Ping
Liu, Zhougang
Liu, Peng
Jing, Hongmei
Gao, Sujun
Zhang, Huilai
Yu, Kang
Wang, Zhao
Zhu, Xiongpeng
Sun, Zimin
Li, Fei
Yan, Dongmei
Weng, Jianyu
Fu, Lina
Wang, Liping
Salmi, Tommi
Wu, Kenneth
Qiu, Lugui
Funding for this research was provided by:
BeiGene USA, Inc.
Article History
Received: 29 January 2024
Accepted: 30 May 2024
First Online: 18 June 2024
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. Written informed consent was obtained from each patient, and institutional review board approval was obtained at each study site.
: L.F., L.W., T.S., and K.W. are employed by BeiGene and may hold company stock/stock options. K.Z., T.W., L.P., W.X., J.J., W.Z., Y.H., J.H., R.F., P.L., Z.L., P.L., H.J., S.G., H.Z., K.Y., Z.W., X.Z., Z.S., F.L., D.Y., and J.W. have nothing to disclose. L.Q. participates in speaker’s bureaus with BeiGene, Janssen, Roche, AstraZeneca, and Takeda.